Skip to search formSkip to main contentSkip to account menu

sirukumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018
ABSTRACT Introduction: Interleukin-6 (IL-6) is well-known for its pro-inflammatory properties, has been proven to target a wide… 
2018
2018
Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis
To characterize the dose‐exposure–response relationship of sirukumab, an anti–interleukin 6 human monoclonal antibody, in the… 
2018
2018
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3…
Abstract Objective: To evaluate the efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis (RA… 
2017
2017
THU0130 Improvement in measures of depressed mood and anhedonia in two randomized, placebo-controlled phase iii studies of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid…
Background Interleukin-6 (IL-6) is one of the known neuroactive-cytokines involved in neuronal plasticity and stress coping and… 
Review
2016
Review
2016
SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo…
Background Sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is under… 
2015
2015
THU0042 Preclinical Characterization of Sirukumab, a Human Monoclonal Antibody that Targets Human Interleukin-6 Signaling
Background A significant fraction of patients with rheumatoid arthritis (RA) have an inadequate response to tumor necrosis factor… 
2015
2015
FRI0069 Neutralization of IL6 by Sirukumab (SIR) Inhibits Inflammation and Cellular Stress in a Human Vascular Surrogate System of Atherosclerosis
Background Rheumatoid arthritis (RA) and atherosclerosis are chronic inflammatory diseases that share pathologic and molecular… 
2014
2014
OP0047 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis
Background Interleukin-6 is a pro-inflammatory cytokine that is over-expressed in LN. Objectives This proof-of-concept study… 
2013
2013
Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
OBJECTIVE Sirukumab (CNTO 136) is a human mAb with high affinity and specificity for binding to interleukin-6. This Phase 1 study… 
2013
2013
OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid…
Objectives To assess remission rates from a phase 2 study of sirukumab, a human monoclonal antibody against the cytokine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)